Shares of Metsera, Inc. (NASDAQ:MTSR - Get Free Report) shot up 5.6% during trading on Thursday . The company traded as high as $29.69 and last traded at $29.69. 86,736 shares were traded during trading, a decline of 87% from the average session volume of 662,272 shares. The stock had previously closed at $28.11.
Analyst Ratings Changes
Several research analysts have recently issued reports on the stock. Guggenheim started coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price objective for the company. Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target on the stock. Cantor Fitzgerald assumed coverage on Metsera in a research note on Tuesday, February 25th. They set an "overweight" rating for the company. Finally, Evercore ISI initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating on the stock.
Get Our Latest Stock Report on MTSR
Metsera Stock Down 2.8 %
Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Articles
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
